Sogen Data · Datasets · 数据专题

乳腺癌复发轴数据集锦

单细胞 · bulk 转录组

本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。

人源单细胞

Human · Single-cell

  1. 01 GSE274139 针对HR+/HER2-转移性乳腺癌患者,收集治疗前基线(BL)样本(n=8)及治疗后早期进展者(EP, n=3)和晚期进展者(LP, n=8)的单细胞RNA,通过单细胞RNA测序分析不同进展阶段的转录特征差异,比较BL与EP、LP及EP与LP之间的差异。 人源 · 35 例 · GPL24676 · 2025/02/18

    设计针对HR+/HER2-转移性乳腺癌患者,收集治疗前基线(BL)样本(n=8)及治疗后早期进展者(EP, n=3)和晚期进展者(LP, n=8)的单细胞RNA,通过单细胞RNA测序分析不同进展阶段的转录特征差异,比较BL与EP、LP及EP与LP之间的差异。

    摘要This study addresses the critical need for predictive biomarkers in patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) who have been treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is). Using single-cell RNA sequencing, we reveal differential mechanisms of early versus late progression, enhancing our understanding of resistance to CDK4/6is. We identify and validate tumor-specific molecular biomarkers and demonstrate that tumor-infiltrating cytotoxic natural killer and CD8+ T cells are predictive of therapeutic response. Additionally, increased immune activity suppression in late progressing tumors suggests that combining CDK4/6is with checkpoint inhibitors could be beneficial against drug resistance. Validation across 2 independent cohorts confirms the robustness and clinical relevance of our findings. These insights pave the way for optimizing therapeutic strategies based on microenvironment-specific changes, offering a personalized and effective approach to managing HR+/HER2- mBC and improving patient outcomes.

  2. 02 GSE164715 对三阴性乳腺癌残留细胞进行单细胞 RNA 测序,研究其在 5-氟尿嘧啶(5FU)处理下的转录组变化,同时分析 HBCx95 患者来源异种移植瘤(PDX)在 5FU 治疗下的细胞命运响应。 人源 · 19 例 · GPL24676 · 2022/02/15

    设计对三阴性乳腺癌残留细胞进行单细胞 RNA 测序,研究其在 5-氟尿嘧啶(5FU)处理下的转录组变化,同时分析 HBCx95 患者来源异种移植瘤(PDX)在 5FU 治疗下的细胞命运响应。

    摘要Triple-negative breast cancer is associated with the worst prognosis and the highest risk of recurrence among all breast cancer subtypes1. Residual disease, formed by cancer cells persistent to chemotherapy, remains the major clinical challenge towards full cure2,3. There is now consensus that non-genetic processes contribute to chemoresistance in various tumor types, notably through the initial emergence of a reversible chemotolerant state4–6. Understanding non-genetic tumor evolution stands now as a prerequisite for the design of relevant combinatorial approaches to delay recurrence. Here we show that the repressive histone mark H3K27me3 is a determinant of cell fate under chemotherapy exposure, monitoring epigenomes, transcriptomes and lineage with single-cell resolution. We identify a reservoir of persister basal cells with EMT markers and activated TGF-β pathway leading to multiple chemoresistance phenotypes. We demonstrate that, in unchallenged cells, H3K27 methylation is a lock to the expression program of persister cells. Promoters are primed with both H3K4me3 and H3K27me3, and removing H3K27me3 is sufficient for their transcriptional activation. Leveraging lineage barcoding, we show that depleting H3K27me3 alters tumor cell fate under chemotherapy insult - a wider variety of tumor cells tolerate chemotherapy. Our results highlight how chromatin landscapes shape the potential of unchallenged cancer cells to respond to therapeutic stress and pave the way for combinatorial therapy with modulators of chromatin.

人源bulk 转录组

Human · Bulk RNA-seq

  1. 01 GSE115577 对护士健康研究 I 和 II 中诊断为侵袭性乳腺癌的受试者,采集肿瘤组织和肿瘤邻近组织进行基因表达分析,比较两组组织的基因表达差异。 人源 · 1577 例 · GPL22920;17585 · 2019/01/08

    设计对护士健康研究 I 和 II 中诊断为侵袭性乳腺癌的受试者,采集肿瘤组织和肿瘤邻近组织进行基因表达分析,比较两组组织的基因表达差异。

    摘要Gene expression data from the Nurses' Health Study

  2. 02 GSE283522 对1,082例FFPE乳腺肿瘤样本进行RNA测序,排除1例因知情同意撤销、4例因FFPE块或切片损坏无法处理、63例因病理检查显示良性/健康组织或DCIS/LCIS、1例因临床数据缺失的样本,最终获得1,013例乳腺肿瘤样本。所有样本采用Macherey Nagel NucleoSpin total RNA FFPE XS试剂盒提取总RNA,使用Qubit RNA HS试剂盒和Agilent High Sensitivity RNA ScreenTape评估RNA质量和数量,DV200值大于15%的样本用于文库构建。文库构建使用Takara SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian试剂盒,每批文库包含1个天然阳性对照样本和每个样本的合成内参对照。文库经Qubit dsDNA HS试剂盒和Agilent High Sensitivity DNA ScreenTape评估后,使用Illumina NovaSeq 6000进行测序,根据文库池大小采用SP、S1、S2或S4流细胞,低复杂度文库加入10% PhiX。采用双端测序(2×100 bp)获取约1亿条读数。 人源 · 1254 例 · GPL24676 · 2024/12/23

    设计对1,082例FFPE乳腺肿瘤样本进行RNA测序,排除1例因知情同意撤销、4例因FFPE块或切片损坏无法处理、63例因病理检查显示良性/健康组织或DCIS/LCIS、1例因临床数据缺失的样本,最终获得1,013例乳腺肿瘤样本。所有样本采用Macherey Nagel NucleoSpin total RNA FFPE XS试剂盒提取总RNA,使用Qubit RNA HS试剂盒和Agilent High Sensitivity RNA ScreenTape评估RNA质量和数量,DV200值大于15%的样本用于文库构建。文库构建使用Takara SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian试剂盒,每批文库包含1个天然阳性对照样本和每个样本的合成内参对照。文库经Qubit dsDNA HS试剂盒和Agilent High Sensitivity DNA ScreenTape评估后,使用Illumina NovaSeq 6000进行测序,根据文库池大小采用SP、S1、S2或S4流细胞,低复杂度文库加入10% PhiX。采用双端测序(2×100 bp)获取约1亿条读数。

    摘要Background: Breast cancer (BCa) is a heterogeneous disease requiring precise diagnostics to guide effective treatment. Current assays fail to adequately address the complex biology of BCa subtypes/risk groups and accurately predict responses to treatments like antibody-drug conjugates (ADCs). To address these limitations, we developed and validated a novel diagnostic, prognostic, and predictive tool, mFISHseq. Methods: Our approach, mFISHseq, integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, allows unbiased profiling of whole transcriptome data, and explicitly quantifies intratumoral heterogeneity. Results: In a retrospective cohort study involving 1,082 FFPE breast tumors, mFISHseq demonstrated high analytical validity with 93% accuracy compared to immunohistochemistry across training and test sets. Our consensus subtyping approach provided near-perfect concordance with other molecular classifiers (κ > 0.85) and reclassified 30% of samples into subtypes with distinct prognostic implications. Consensus risk groups mitigated misclassification of single samples and provided prognostic information about both early and late relapse. High risk patients had enriched innate and adaptive immune signatures, which predicted response to neoadjuvant immunotherapy. Furthermore, we identified patients responsive to ADCs, as evidenced by a 19-feature classifier for T-DM1 sensitivity, validated on the multicenter, phase II, prospective I-SPY2 trial. To demonstrate the clinical potential, we deployed mFISHseq as a research use only test on 48 patients, revealing insights into the efficacy of novel targeted therapies, such as CDK4/6 inhibitors, immune checkpoint inhibitors, and ADCs. Conclusion: The mFISHseq method solves a long-standing challenge in the precise diagnosis and classification of BCa subtypes/prognostic risk groups, and allows accurate response prediction for patients, including those treated with immunotherapies and ADCs.

  3. 03 GSE326778 将激素受体阳性HER2阴性乳腺癌患者按AJCC分期(I、IIB、IIA、III、IV)分组,采集组织样本进行转录分析,比较不同分期间的转录特征变化。 人源 · 1152 例 · GPL96 · 2026/06/26

    设计将激素受体阳性HER2阴性乳腺癌患者按AJCC分期(I、IIB、IIA、III、IV)分组,采集组织样本进行转录分析,比较不同分期间的转录特征变化。

    摘要It is important to understand how the biology of breast cancer might differ with the burden of disease. Analyzing the expression of cancer-relevant genes with increasing diagnostic stage can provide insight into the changing biology of breast cancer and is therefore clinically useful. Here, we evaluated the transcriptional activity according to stage of breast cancer (American Joint Commission on Cancer, AJCC Stage I to IV) from 1,152 patients with hormone receptor-positive HER2-negative breast cancer. Samples were prospectively collected fresh for clinical/translational research with transcriptional profiling. Most transcriptional signatures remained consistent across stage categories, while most of the significant changes associated with increasing stage were attributed to endocrine escape, decreasing differentiation, increased complexity of signal transduction, and some metabolic changes. The clinical relevance and implications of these findings are discussed, and the public availability of these expression data from high-quality samples is a resource for researchers.

  4. 04 GSE199633 对637例人类原发性乳腺肿瘤样本进行基因表达分析,研究对象为接受手术治疗的乳腺癌患者,样本为宏观解离的原发性乳腺肿瘤组织。采用Affymetrix微阵列平台检测基因表达,主要比较肿瘤复发与未复发患者的基因表达差异。 人源 · 637 例 · GPL15048 · 2024/06/07

    设计对637例人类原发性乳腺肿瘤样本进行基因表达分析,研究对象为接受手术治疗的乳腺癌患者,样本为宏观解离的原发性乳腺肿瘤组织。采用Affymetrix微阵列平台检测基因表达,主要比较肿瘤复发与未复发患者的基因表达差异。

    摘要We performed gene set enrichment and differential expression analysis to identify biological pathways associated with locoregional recurrence in primary breast tumors. A custom Affymetrix microarray genechip was used to assess the gene expression of each tumor sample.

  5. 05 GSE4922 对347例侵袭性乳腺肿瘤进行基因表达分析,使用Affymetrix microarrays检测,通过SWS分类器识别出与遗传学分级相关的标志物,将遗传学分级分为1-like和3-like两类,并与组织学分级进行比较。 人源 · 578 例 · GPL96;97 · 2006/05/31

    设计对347例侵袭性乳腺肿瘤进行基因表达分析,使用Affymetrix microarrays检测,通过SWS分类器识别出与遗传学分级相关的标志物,将遗传学分级分为1-like和3-like两类,并与组织学分级进行比较。

    摘要Histological grading of breast cancer defines morphological subtypes informative of metastatic potential, although not without considerable inter-observer disagreement and clinical heterogeneity particularly among the moderately differentiated grade II (G2) tumors. We posited that a gene expression signature capable of discerning tumors of grade I (G1) and grade III (G3) histology might provide a more objective measure of grade with prognostic benefit for patients with moderately differentiated disease. To this end, we studied the expression profiles of 347 primary invasive breast tumors analyzed on Affymetrix microarrays. Using class prediction algorithms, we identified 264 robust grade-associated markers, six of which could accurately classify G1 and G3 tumors, and separate G2 tumors into two highly discriminant classes (termed G2a and G2b genetic grades) with patient survival outcomes highly similar to those with G1 and G3 histology, respectively. Statistical analysis of conventional clinical variables further distinguished G2a and G2b subtypes from each other, but also from histologic G1 and G3 tumors. In multivariate analyses, genetic grade was consistently found to be an independent prognostic indicator of disease recurrence comparable to that of lymph node status and tumor size. When incorporated into the Nottingham Prognostic Index, genetic grade enhanced detection of patients with less harmful tumors, likely to benefit little from adjuvant therapy. Our findings show that a genetic grade signature can improve prognosis and therapeutic planning for breast cancer patients, and support the view that low and high grade disease, as defined genetically, reflect independent pathobiological entities rather than a continuum of cancer progression. Three separate breast cancer cohorts were analyzed: 1) Uppsala (n=249), 2) Stockholm (n=58), 3) Singapore (n=40). The Uppsala and Singapore data can be accessed here. The Stockholm cohort data can be accessed at GEO Series GSE1456. Keywords: Tumor sample comparisons

  6. 06 GSE103746 对乳腺癌术后患者进行基因表达分析,研究对象为接受放疗的患者与未接受放疗的患者,采集其组织样本进行 bulk RNA 测序,比较两组间基因表达差异。 人源 · 508 例 · GPL10558;24000 · 2018/07/01

    设计对乳腺癌术后患者进行基因表达分析,研究对象为接受放疗的患者与未接受放疗的患者,采集其组织样本进行 bulk RNA 测序,比较两组间基因表达差异。

    摘要This SuperSeries is composed of the SubSeries listed below.

  7. 07 GSE18229 对乳腺癌复发的bulk RNA样本进行基因表达分析,研究对象为乳腺肿瘤组织,分组包括不同亚型(如Luminal A、Luminal B、HER2+/ER-、Basal-like、Normal-like、Claudin-low等),各组样本按年龄、ER状态、节点状态、分级、肿瘤大小等特征分选,采集乳腺肿瘤组织进行表达检测,比较不同亚型的基因表达差异。 人源 · 372 例 · GPL887;1390;885;5325;1708;6607;7504 · 2010/06/15

    设计对乳腺癌复发的bulk RNA样本进行基因表达分析,研究对象为乳腺肿瘤组织,分组包括不同亚型(如Luminal A、Luminal B、HER2+/ER-、Basal-like、Normal-like、Claudin-low等),各组样本按年龄、ER状态、节点状态、分级、肿瘤大小等特征分选,采集乳腺肿瘤组织进行表达检测,比较不同亚型的基因表达差异。

    摘要In breast cancer, gene expression analyses have defined five tumor subtypes, each of which has unique biologic and prognostic features. Here, we characterize the recently identified claudin-low tumor subtype as showing low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes, and cancer stem cell–like features. Clinically, most claudin-low tumors are poorprognosis estrogen receptor–negative, progesterone receptor–negative, and human epidermal growth factor receptor 2–negative (triple-negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Moreover, we show that a group of highly used breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell. These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.

  8. 08 GSE30682 对343例原发性乳腺癌样本的基因表达数据进行分析,以识别与局部复发相关的基因表达特征,特别关注年轻女性群体。采用Illumina HumanWG-6_v3 Arrays检测技术,样本按是否发生局部复发(lr: 0/1)及复发时间(time2lr: 2.1, 1.4, 3.4等)特征分类,未明确描述分组处理条件。 人源 · 343 例 · GPL6884 · 2012/02/04

    设计对343例原发性乳腺癌样本的基因表达数据进行分析,以识别与局部复发相关的基因表达特征,特别关注年轻女性群体。采用Illumina HumanWG-6_v3 Arrays检测技术,样本按是否发生局部复发(lr: 0/1)及复发时间(time2lr: 2.1, 1.4, 3.4等)特征分类,未明确描述分组处理条件。

    摘要Kreike et al, have constructed a gene-expression (GE) profile predictive for local recurrence (LR) after breast-conserving treatment (BCT) from a series of 165 patients . This study aimed to test this signature both internally (cross-platform) and externally on a independent series and to further explore the search for a GE signature of breast cancer LR in young women.

  9. 09 GSE45725 对340例乳腺癌患者进行细针穿刺活检,采集肿瘤组织样本进行微阵列分析,最终使用其中284例浸润性乳腺癌样本用于ClinicoMolecular Triad Classification的开发。 人源 · 340 例 · GPL6883 · 2014/06/19

    设计对340例乳腺癌患者进行细针穿刺活检,采集肿瘤组织样本进行微阵列分析,最终使用其中284例浸润性乳腺癌样本用于ClinicoMolecular Triad Classification的开发。

    摘要In our early study (PMID: 21939527), we have created a ClinicoMolecular Triad Classification (CMTC) to improve prediction and prognostication of breast cancer by using a training cohort contained 161 breast cancer patients (2003 to 2008). Here, a supplemental internal validation cohort contained 340 breast cancer patients was collected (2008 to 2010) for development of the CMTC.

  10. 10 GSE103745 对接受乳腺癌保乳手术(BCS)的336名乳腺癌患者的新鲜冷冻肿瘤组织进行总RNA提取,并使用定制的Nanostring nCounter检测平台进行分析。患者分为发现队列(N=172)和验证队列(N=164),基于Illumina HT12 v4全转录组分析中预测同侧乳腺肿瘤复发(IBTR)的基因与文献中248个基因结合,开发针对放射敏感性的靶向检测。采用k-top评分对单样本预测因子(SSPs)进行训练,按雌激素受体(ER)状态和放射治疗(RT)分层。同时测试了两种已发表的放射敏感性指数(RSI)和放射敏感性评分(RSS)模型。 人源 · 336 例 · GPL24000 · 2018/07/01

    设计对接受乳腺癌保乳手术(BCS)的336名乳腺癌患者的新鲜冷冻肿瘤组织进行总RNA提取,并使用定制的Nanostring nCounter检测平台进行分析。患者分为发现队列(N=172)和验证队列(N=164),基于Illumina HT12 v4全转录组分析中预测同侧乳腺肿瘤复发(IBTR)的基因与文献中248个基因结合,开发针对放射敏感性的靶向检测。采用k-top评分对单样本预测因子(SSPs)进行训练,按雌激素受体(ER)状态和放射治疗(RT)分层。同时测试了两种已发表的放射敏感性指数(RSI)和放射敏感性评分(RSS)模型。

    摘要Purpose To develop a radiosensitivity gene expression assay to predict the response to adjuvant radiotherapy (RT) after breast conserving surgery (BCS) in breast cancer. Patients and methods Fresh frozen primary tumors from 336 patients operated with BCS with or without RT were collected. Patients were split in a discovery cohort (N=172) and a validation cohort (N=164). Genes predicting ipsilateral breast tumor recurrence (IBTR) in an Illumina HT12 v4 whole transcriptome analysis were combined with genes from the literature (248 genes in total) to develop a targeted radiosensitivity assay on the Nanostring nCounter platform. Single sample predictors (SSPs) for IBTR based on a k-top scoring pairs algorithm were trained stratified for estrogen receptor (ER) status and RT. Two previously published profiles (radiosensitivity index, RSI, and radiosensitivity score, RSS) were also tested in our data Results The SSPs were prognostic for IBTR in ER+RT- patients (AUC 0.67, p=0.005), ER+RT- patients (AUC=0.89, p=0.015) and ER-RT+ patients (AUC=0.78, p<0.001). Among ER+ patients, radiosensitive tumors had an excellent effect of RT (p<0.001), while radioresistant tumors had no effect of RT (p=0.4) and a high risk of IBTR (55% at 10 years). Our SSPs developed in ER+ tumors and the RSS correlated with proliferation, while SSPs developed in ER- tumors correlated with immune response. RSI negatively correlated with both proliferation and immune response. Conclusions Our targeted SSPs were prognostic for IBTR and has the potential to stratify patients for RT. The biology behind models may explain the different performance in subgroups of breast cancer. Purpose To develop a radiosensitivity gene expression assay to predict the response to adjuvant radiotherapy (RT) after breast conserving surgery (BCS) in breast cancer. Patients and methods Fresh frozen primary tumors from 336 patients operated with BCS with or without RT were collected. Patients were split in a discovery cohort (N=172) and a validation cohort (N=164). Genes predicting ipsilateral breast tumor recurrence (IBTR) in an Illumina HT12 v4 whole transcriptome analysis were combined with genes from the literature (248 genes in total) to develop a targeted radiosensitivity assay on the Nanostring nCounter platform. Single sample predictors (SSPs) for IBTR based on a k-top scoring pairs algorithm were trained stratified for estrogen receptor (ER) status and RT. Two previously published profiles (radiosensitivity index, RSI, and radiosensitivity score, RSS) were also tested in our data Results The SSPs were prognostic for IBTR in ER+RT- patients (AUC 0.67, p=0.005), ER+RT- patients (AUC=0.89, p=0.015) and ER-RT+ patients (AUC=0.78, p<0.001). Among ER+ patients, radiosensitive tumors had an excellent effect of RT (p<0.001), while radioresistant tumors had no effect of RT (p=0.4) and a high risk of IBTR (55% at 10 years). Our SSPs developed in ER+ tumors and the RSS correlated with proliferation, while SSPs developed in ER- tumors correlated with immune response. RSI negatively correlated with both proliferation and immune response. Conclusions Our targeted SSPs were prognostic for IBTR and has the potential to stratify patients for RT. The biology behind models may explain the different performance in subgroups of breast cancer.

  11. 11 GSE1456 从1994-1996年在Karolinska医院接受手术的乳腺癌患者中收集组织材料,立即用干冰或液氮冷冻并保存于-70°C冰箱中。该系列包含159个可提取足够量和质量RNA的肿瘤样本,使用Affymetrix Microarray Suite Version 5.0进行表达分析,所有肿瘤样本均在U133 A和B芯片上检测,未明确分组或处理条件。 人源 · 318 例 · GPL96;97 · 2006/05/31

    设计从1994-1996年在Karolinska医院接受手术的乳腺癌患者中收集组织材料,立即用干冰或液氮冷冻并保存于-70°C冰箱中。该系列包含159个可提取足够量和质量RNA的肿瘤样本,使用Affymetrix Microarray Suite Version 5.0进行表达分析,所有肿瘤样本均在U133 A和B芯片上检测,未明确分组或处理条件。

    摘要Tissue material was collected from all breast cancer patients receiving surgery at Karolinska Hospital from 1994-1996. Material was frozen immediatley on dry ice or in liquid nitrogen and stored in -70°C freezers. This series contains expression data for n=159 tumors from which RNA could be collected in sufficient amounts and quality for analysis. Keywords: breast cancer, expression profiling, predictive gene signature, molecular classification of cancecr

  12. 12 GSE32603 对局部晚期乳腺癌患者在未达到病理完全缓解的情况下,分析治疗前活检(T1)与治疗后24-72小时活检(T2)或化疗后手术切除肿瘤(TS)的基因表达数据,比较T1与T2、T1与TS的差异。 人源 · 248 例 · GPL14668 · 2015/06/12

    设计对局部晚期乳腺癌患者在未达到病理完全缓解的情况下,分析治疗前活检(T1)与治疗后24-72小时活检(T2)或化疗后手术切除肿瘤(TS)的基因表达数据,比较T1与T2、T1与TS的差异。

    摘要To elucidate candidate genes and pathways associated with poor response, we retrospectively analyzed gene expression profiles in serial biopsies from women with locally advanced breast cancer who failed to respond to anthracycline-based chemo followed by taxane in the I-SPY

  13. 13 GSE92977 对乳腺癌患者匹配的原发肿瘤和转移性肿瘤样本进行基因表达分析,检测总 RNA 中 105 个乳腺癌相关基因的表达水平,比较原发与转移性样本的基因表达差异。 人源 · 246 例 · GPL17071 · 2017/01/08

    设计对乳腺癌患者匹配的原发肿瘤和转移性肿瘤样本进行基因表达分析,检测总 RNA 中 105 个乳腺癌相关基因的表达水平,比较原发与转移性样本的基因表达差异。

    摘要We compared expression of 105 breast cancer-related genes between matched primary and metastatic breast cancer

  14. 14 GSE22219 对早期原发性乳腺癌患者进行回顾性研究,采集其肿瘤组织进行基因表达分析,以识别预后标志物及相关通路。研究纳入 216 例具有完整 10 年随访数据的患者,根据年龄、肿瘤大小、淋巴结状态和激素受体状态分组,接受不同辅助治疗方案,包括他莫昔芬内分泌治疗、环磷酰胺-甲氨蝶呤-5-氟尿嘧啶(CMF)化疗,或不接受辅助治疗。主要比较不同治疗组与未治疗组的远处复发风险及无远处复发生存期。 人源 · 216 例 · GPL6098 · 2011/07/08

    设计对早期原发性乳腺癌患者进行回顾性研究,采集其肿瘤组织进行基因表达分析,以识别预后标志物及相关通路。研究纳入 216 例具有完整 10 年随访数据的患者,根据年龄、肿瘤大小、淋巴结状态和激素受体状态分组,接受不同辅助治疗方案,包括他莫昔芬内分泌治疗、环磷酰胺-甲氨蝶呤-5-氟尿嘧啶(CMF)化疗,或不接受辅助治疗。主要比较不同治疗组与未治疗组的远处复发风险及无远处复发生存期。

    摘要Retrospective series of primary breast cancer patients who received surgery between 1989 and 1992. Patients received adjuvant chemotherapy and/or adjuvant hormone therapy, or no adjuvant treatment. Tamoxifen was used as endocrine therapy for 5 years in ER+ BC patients. Patients who were <50 years of age, with lymph node positive tumors, or ER– and/or >3 cm in diameter, received adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for six cycles, in a thrice weekly intravenous regimen. Patients >50 years of age with ER–, lymph node–positive tumors also received CMF.

  15. 15 GSE12276 从具有已知复发部位的乳腺癌患者中收集了204例原发性肿瘤样本,聚焦于脑部复发与非脑部复发的比较。通过转录组分析识别出与脑部复发相关的基因,并在该队列中验证这些基因。 人源 · 204 例 · GPL570 · 2009/06/13

    设计从具有已知复发部位的乳腺癌患者中收集了204例原发性肿瘤样本,聚焦于脑部复发与非脑部复发的比较。通过转录组分析识别出与脑部复发相关的基因,并在该队列中验证这些基因。

    摘要Brain metastasis is one of the most feared complications of cancer and the most common intracranial malignancy in adults. Its underlying mechanisms remain unknown. From breast cancer patients with metastatic disease we isolated cell populations that aggressively colonize the brain. Transcriptomic analysis of these cells yielded overlapping gene sets whose expression is selectively associated with brain metastasis. The expression of seventeen of these genes in primary breast tumors is associated with brain relapse in breast cancer patients. Some of these genes are also associated with metastasis to lung but not to liver, bone or lymph nodes, providing a molecular basis for the long-observed link between brain and lung metastasis. Among the functionally validated brain metastasis genes, the cyclooxigenase COX-2, the EGFR ligand HB-EGF, and the brain-specific 2-6 sialyltransferase ST6GALNAC5 mediate cancer cell passage through the blood-brain barrier. Other brain metastasis genes encode inflammatory factors and brain-specific proteolytic regulators, suggesting a multifaceted program for breast cancer colonization of the brain. Keywords: Disease state comparison

  16. 16 GSE6128 对乳腺癌复发的bulk RNA样本进行表达分析,研究对象为不同亚型的乳腺癌组织,包括Basal-like、Luminal B、Luminal A、HER2?、Normal-like及正常乳腺组织,采用Agilent Custom Replicate Array平台进行检测,主要比较各亚型在EGFR信号通路相关基因表达上的差异。 人源 · 191 例 · GPL1390;887 · 2007/08/20

    设计对乳腺癌复发的bulk RNA样本进行表达分析,研究对象为不同亚型的乳腺癌组织,包括Basal-like、Luminal B、Luminal A、HER2?、Normal-like及正常乳腺组织,采用Agilent Custom Replicate Array平台进行检测,主要比较各亚型在EGFR信号通路相关基因表达上的差异。

    摘要Our research data suggest that almost all basal-like tumors have an EGFR-activation profile, however, few may respond to the direct inhibition of EGFR due to ligand independent activation of the EGFR-RAS-MEK pathway via CRYAB or KRAS function. Thus, for those tumors that show a ligand independent EGFR-activation profile, alternative strategies that target downstream components like MEK may prove to be viable alternatives. Keywords: reference x sample

  17. 17 GSE2990 对189例侵袭性乳腺癌肿瘤样本进行基因表达分析,比较组织学分级1与3的差异以识别差异表达基因,并利用这些基因定义基因表达分级指数。使用597例独立肿瘤样本评估该指数与无病生存期的关系,通过Kaplan-Meier分析进行比较。 人源 · 189 例 · GPL96 · 2006/02/16

    设计对189例侵袭性乳腺癌肿瘤样本进行基因表达分析,比较组织学分级1与3的差异以识别差异表达基因,并利用这些基因定义基因表达分级指数。使用597例独立肿瘤样本评估该指数与无病生存期的关系,通过Kaplan-Meier分析进行比较。

    摘要Background: Histologic grade in breast cancer provides clinically important prognostic information. However, 30%-60% of tumors are classified as histologic grade 2. This grade is associated with an intermediate risk of recurrence and is thus not informative for clinical decision making. We examined whether histologic grade was associated with gene expression profi les of breast cancers and whether such profi les could be used to improve histologic grading. Methods: We analyzed microarray data from 189 invasive breast carcinomas and from three published gene expression datasets from breast carcinomas. We identified differentially expressed genes in a training set of 64 estrogen receptor (ER)-positive tumor samples by comparing expression profiles between histologic grade 3 tumors and histologic grade 1 tumors and used the expression of these genes to define the gene expression grade index. Data from 597 independent tumors were used to evaluate the association between relapse-free survival and the gene expression grade index in a Kaplan-Meier analysis. All statistical tests were two-sided. Results: We identified 97 genes in our training set that were associated with histologic grade; most of these genes were involved in cell cycle regulation and proliferation. In validation datasets, the gene expression grade index was strongly associated with histologic grade 1 and 3 status; however, among histologic grade 2 tumors, the index spanned the values for histologic grade 1-3 tumors. Among patients with histologic grade 2 tumors, a high gene expression grade index was associated with a higher risk of recurrence than a low gene expression grade index (hazard ratio = 3.61, 95% confidence interval = 2.25 to 5.78; P<.001, log-rank test). Conclusions: Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence. This approach may improve the accuracy of tumor grading and thus its prognostic value. NB: The patients coming from Uppsala Hospital have been also used in other studies as in GSE3494. You can find the common set of patients in removing the abbreviation "UPP_" from the sample names and compare the results with the "INDEX (ID)" from the GSE3494 series. Keywords: disease state analysis

  18. 18 GSE1992 对乳腺癌复发样本进行批量RNA测序,分析其内在亚型特征,比较不同内在亚型的复发无病生存期和总生存期。研究对象为乳腺癌复发样本,检测方式为批量RNA测序,主要比较不同内在亚型的生存数据。 人源 · 170 例 · GPL887;1390;885 · 2005/12/08

    设计对乳腺癌复发样本进行批量RNA测序,分析其内在亚型特征,比较不同内在亚型的复发无病生存期和总生存期。研究对象为乳腺癌复发样本,检测方式为批量RNA测序,主要比较不同内在亚型的生存数据。

    摘要Breast cancer is a difficult disease to manage because it is comprised of a spectrum of tumor subtypes with different biological characteristics. Previous gene expression studies using breast tumor “intrinsic” gene lists identified five distinct subtypes of breast tumors: Luminal A, Luminal B, Normal Breast-like, HER2+/ER- and Basal-like. Using a training data set of 102 unique breast tumors, we derive a new “intrinsic” gene list based upon 26 paired samples. This Intrinsic/UNC gene set recapitulates the old classifications and extends the analysis to include a large proliferation signature, which was lacking before. Using Distance Weighted Discrimination, we next created a true “test set” of 311 tumors by combining together three different publicly available breast tumor microarray data sets (1-3), which was then analyzed using the newly derived Intrinsic/UNC gene set. The test set analysis identified the same five intrinsic subtypes seen before and a new one (Luminal I), and we show that the intrinsic subtype classifications are independent predictors of relapse-free survival when adjusting for age, node status, tumor size, grade and ER status. We also developed a “Single Sample Predictor” that is able to assign an intrinsic subtype to one sample at a time, which was also shown to be predictive of outcomes on another independent test set of tamoxifen-treated ER+ patients. These analyses demonstrate that 1) common patterns of expression can be identified across different microarray platforms, 2) the breast tumor “intrinsic” subtypes are present in all breast tumor data sets studied, and 3) this classification is adding value to the existing repertoire of clinical markers for breast cancer patients. Keywords: parallel sample

  19. 19 GSE2741 对乳腺癌复发样本进行批量RNA测序,与细胞系进行比较,分析其基因表达特征。 人源 · 169 例 · GPL887;1390;885 · 2005/11/23

    设计对乳腺癌复发样本进行批量RNA测序,与细胞系进行比较,分析其基因表达特征。

    摘要Microarray analysis has been shown to improve risk stratification of breast cancer. Breast tumors analyzed by hierarchical clustering of expression patterns of "intrinsic" genes have been reported to subdivide into at least four molecular subtypes that are associated with distinct patient outcomes. Using a supervised method, a 70-gene expression profile has been identified that predicts the later appearance or absence of clinical metastasis in young breast cancer patients. Here, we show that distant metastases display both the same molecular breast cancer subtype as well as the 70-gene prognosis signature as their primary tumors. Our results suggest that the capacity to metastasize is an inherent feature of most breast cancers. Furthermore, our data imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process. Keywords: other

  20. 20 GSE9893 利用 132 例他莫昔芬治疗的原发性乳腺癌患者肿瘤样本的基因表达谱,构建了一个包含 36 个基因的分子分类器。该分类器通过 70-mer 寡核苷酸微阵列平台进行全基因组水平的表达分析,并使用 83 例独立肿瘤样本的表达数据验证其稳健性。研究对象为人类乳腺原发性肿瘤组织,检测方式为微阵列基因表达分析,主要比较不同肿瘤样本的基因表达差异。 人源 · 155 例 · GPL5049 · 2008/03/18

    设计利用 132 例他莫昔芬治疗的原发性乳腺癌患者肿瘤样本的基因表达谱,构建了一个包含 36 个基因的分子分类器。该分类器通过 70-mer 寡核苷酸微阵列平台进行全基因组水平的表达分析,并使用 83 例独立肿瘤样本的表达数据验证其稳健性。研究对象为人类乳腺原发性肿瘤组织,检测方式为微阵列基因表达分析,主要比较不同肿瘤样本的基因表达差异。

    摘要A 36-gene classifier was constructed through expression profiling of 132 tumors from tamoxifen-treated patients using 70-mer oligonucleotide microarrays. The robustness of the signature was demonstrated using expression data from 83 independent tumors. The 36-gene signature was (i) more efficient to predict disease-free survival than the traditional histo-pathological prognostic factors, (ii) as effective as the Nottingham Prognostic Index or the "Adjuvant!" software, and (iii) the only independent prognostic factor. Comparison with several already published signatures demonstrated that the 36-gene signature was among the best to classify tumors. Keywords: Gene expression profiling; supervised analysis; molecular signature predictive of recurrence; univariate and multivariate analysis in relation to disease-free survival.

  21. 21 GSE22226 将乳腺癌复发的bulk RNA数据与参考样本进行比较,通过磁共振成像(MRI)测量肿瘤体积变化和完全病理反应,分组依据分子亚型,研究对象为接受新辅助化疗(AC加可选紫杉类药物)的T=3 cm乳腺癌患者。 人源 · 150 例 · GPL1708;4133 · 2012/01/13

    设计将乳腺癌复发的bulk RNA数据与参考样本进行比较,通过磁共振成像(MRI)测量肿瘤体积变化和完全病理反应,分组依据分子亚型,研究对象为接受新辅助化疗(AC加可选紫杉类药物)的T=3 cm乳腺癌患者。

    摘要Introduction: The I-SPY 1 TRIAL was designed to evaluate complete pathologic response and tumor volume change, measured by magnetic resonance imaging (MRI), stratified by molecular subtypes and link response to 3-year recurrence free survival (RFS).Methods: Eligible patients had T =3 cm and received neoadjuvant chemotherapy with AC plus optional taxane. Serial MRI, biopsy, and blood draws were conducted over the course of treatment, and a database of multiple molecular profiles was assembled.Results: A total of 221 patients were eligible for analysis: median tumor size was 6.0 cm and median age was 49 years. The I-SPY 1 TRIAL patients had tumors with aggressive biology: 45% were estrogen receptor (ER) negative, 31% Her2+; and 91% high risk by the Netherlands Cancer Institute (NKI) 70-gene profile. After a median of 3.9 years, RFS was 77%. HR/HER2 status improved predictability of RFS with the greatest difference between HR+/HER2- and triple-negative disease (hazard ratio 0.39). Wound healing signature activation, p53 mutation, and Risk of Relapse (ROR) score were highly correlated and also significantly improved the accuracy of RFS predictions when added to stage. The rate of pathologic complete response (pCR) varied considerably from a low of 0-2% (NKI low risk, luminal A) to a high of 43-61% (17q Amplified, HER2 enriched, HR-/HER2+). Both pCR and the more refined residual cancer burden (RCB) were significant predictors of RFS for all patients and even more predictive when analyzed within biomarker subsets. Good risk (NKI low, ROR-S low risk, Wound Healing quiescent, p53 wild type) signatures were associated with significantly higher 3-year RFS than poor risk expression signatures (ROR-S high risk, Wound Healing Activated, p53 mutation, NKI high risk).Conclusion: Importantly, in this set of biologically poor prognosis tumors, pCR predicts for better outcome, especially when analyzed within breast cancer subsets. Keywords: reference x sample

  22. 22 GSE31863 对乳腺癌复发患者进行基因表达分析,比较不同组别(LR+RT+、LR-RT+、LR+RT-、LR-RT-)的肿瘤组织基因表达特征,采用双通道芯片技术,其中一通道为肿瘤样本,另一通道为参考样本。 人源 · 143 例 · GPL14374 · 2011/09/03

    设计对乳腺癌复发患者进行基因表达分析,比较不同组别(LR+RT+、LR-RT+、LR+RT-、LR-RT-)的肿瘤组织基因表达特征,采用双通道芯片技术,其中一通道为肿瘤样本,另一通道为参考样本。

    摘要Gene expression profiling of breast tumors for prognosis of local reccurence.

  23. 23 GSE9309 将乳腺癌复发的肿瘤组织与非肿瘤组织样本进行比较,使用Agilent两色微阵列技术分析基因表达,通过子组标准化方法补偿不同缓冲液(Buffer1和Buffer2)带来的技术异质性。所有样本均采用Trizol试剂结合Rneasy mini kit提取总RNA,肿瘤样本(98例)与非肿瘤样本(8例)均使用Buffer1杂交,对照组可能使用Buffer2处理。 人源 · 142 例 · GPL887 · 2007/10/20

    设计将乳腺癌复发的肿瘤组织与非肿瘤组织样本进行比较,使用Agilent两色微阵列技术分析基因表达,通过子组标准化方法补偿不同缓冲液(Buffer1和Buffer2)带来的技术异质性。所有样本均采用Trizol试剂结合Rneasy mini kit提取总RNA,肿瘤样本(98例)与非肿瘤样本(8例)均使用Buffer1杂交,对照组可能使用Buffer2处理。

    摘要Recovery of biological information (i.e. Breast tumor versus non-tumor part of breast) from microarray data under heterogeneous experimental conditions (Buffer1 versus Buffer2) using subgroup standardization. Microarray is a useful tool for gene expression analysis and prediction. For a given disease, a microarray database may come from various sources with different experimental setups, collected over time. This heterogeneity provides unnecessary complication in data analysis and, even worse, given false classification in clustering. Therefore, it is practically important to provide a standard data treatment for microarray data from heterogeneous experimental conditions. In this work, “subgroup standardization” is proposed to compensate technical heterogeneities (e.g., buffers, time, machines etc.) in microarray experimental conditions. Provided with repetitive microarray experiments, over time and buffers, the results indicate that the proposed approach can extract correct biological information in the presence of technical irregularities. Hierarchical clustering is used to validate the effectiveness of the proposed approach. Keywords: disease state study

  24. 24 GSE45255 将来自 Institut Jules Bordet (IJB)、John Radcliffe Hospital (JRH) 和 National University Hospital (NUH) 的乳腺肿瘤样本进行 Affymetrix U133A 平台的表达谱分析,样本分别来自 1994-2001 年、1990-1993 年和 2000-2002 年,样本量分别为 41、8 和 100。 人源 · 139 例 · GPL96 · 2013/03/21

    设计将来自 Institut Jules Bordet (IJB)、John Radcliffe Hospital (JRH) 和 National University Hospital (NUH) 的乳腺肿瘤样本进行 Affymetrix U133A 平台的表达谱分析,样本分别来自 1994-2001 年、1990-1993 年和 2000-2002 年,样本量分别为 41、8 和 100。

    摘要To facilitate a better understanding of the molecular heterogeneity of breast cancer and to uncover gene-survival associations that segregate with distinct molecular subtypes, we recently compiled a meta-analytical database of over 2,000 human breast tumor expression profiles variously annotated for clinical and pathological variables and derived from various institutions worldwide. This database was utilized for the breast tumor study cited below: Nagalla, et. al., Genome Biology, 2013. While the majority of the tumor expression profiles included in this database derived from publicly accessible microarray repositories, a number of the samples had not been previously published. Here, we describe the origin of these samples and provide their associated clinical and pathological annotations with the hope that other investigators will be able to utilize these data in their own research.

  25. 25 GSE162228 将109例台湾乳腺癌样本(24例含邻近正常乳腺组织)通过Affymetrix微阵列平台进行基因表达分析,同时对96例样本使用NanoString nCounter平台进行PAM50分子亚型检测,其中61例样本在两种平台上均进行了检测。所有样本均为乳腺癌肿瘤组织,采用邻近质心法进行分子亚型分类。 人源 · 133 例 · GPL570 · 2021/09/01

    设计将109例台湾乳腺癌样本(24例含邻近正常乳腺组织)通过Affymetrix微阵列平台进行基因表达分析,同时对96例样本使用NanoString nCounter平台进行PAM50分子亚型检测,其中61例样本在两种平台上均进行了检测。所有样本均为乳腺癌肿瘤组织,采用邻近质心法进行分子亚型分类。

    摘要Five molecular subtypes have been identified according to intrinsic genes transcription. Microarrays have been adopted for molecular subtyping in addition to the original NanoString nCounter assay. This study aimed to evaluate subtyping consistency among Taiwanese breast cancers. Our study showed that fundamental discrepancy exists between distinct gene expression measuring approaches, and cross platform equivalence should not be overemphasized with too much extrapolation.

  26. 26 GSE119937 对接受乳腺癌切除术但未接受术后放疗的乳腺癌患者进行分子异常分析,比较局部复发(LRR)和远处转移(DM)患者与非复发对照组的差异。研究对象为HER2阴性、未接受治疗、T1-3和N0-1阶段的乳腺癌患者,共131例样本。RNA测序用于分析原发肿瘤,DNA分析用于检测NF1突变和MAPK通路基因突变,主要比较LRR、DM与对照组的分子特征。 人源 · 131 例 · GPL11154 · 2018/09/14

    设计对接受乳腺癌切除术但未接受术后放疗的乳腺癌患者进行分子异常分析,比较局部复发(LRR)和远处转移(DM)患者与非复发对照组的差异。研究对象为HER2阴性、未接受治疗、T1-3和N0-1阶段的乳腺癌患者,共131例样本。RNA测序用于分析原发肿瘤,DNA分析用于检测NF1突变和MAPK通路基因突变,主要比较LRR、DM与对照组的分子特征。

    摘要Breast cancer (BC) adjuvant therapy after mastectomy in the setting of 1-3 positive lymph nodes has been controversial. This retrospective Translational Breast Cancer Research Consortium study evaluated molecular aberrations in primary cancers associated with locoregional recurrence (LRR) or distant metastasis (DM) compared to non-recurrent controls. We identified 115 HER2 negative, therapy naïve, T 1-3 and N 0-1 BC patients treated with mastectomy but no post-mastectomy radiotherapy. This included 32 LRR, 34 DM and 49 controls. RNAseq was performed on primary tumors in 110 patients; with no difference in RNA profiles between patients with LRR, DM or controls. DNA analysis on 57 primary tumors (17 LRR, 15 DM and 25 controls) identified significantly more NF1 mutations and mitogen activated protein kinase (MAPK) pathway gene mutations in patients with LRR (24%, 47%) and DM (27%, 40%) compared to controls (0%, 0%; p<0.0001 and p=0.0070, respectively). Three patients had matched primary vs LRR samples, one patient had a gain of a NF1 mutation in the LRR. There was no significant difference between the groups for PTEN loss or cleaved caspase 3 expression. The mean percentage Ki 67 labeling index was higher in patients with LRR (29.2%) and DM (26%) versus controls (14%,p= 0.0045). In summary, mutations in the MAPK pathway, specifically NF1, were associated with both LRR and DM, suggesting that alterations in MAPK signaling are associated with a more aggressive tumor phenotype. Validation of these associations in tissues from randomized trials may support targeted therapy to reduce breast cancer recurrence.

  27. 27 GSE69031 对乳腺癌复发患者和非复发患者的乳腺组织进行总 RNA 提取,采用 GPL571 平台进行表达谱分析,比较两组间基因表达差异。 人源 · 130 例 · GPL571 · 2015/05/20

    设计对乳腺癌复发患者和非复发患者的乳腺组织进行总 RNA 提取,采用 GPL571 平台进行表达谱分析,比较两组间基因表达差异。

    摘要We measured baseline gene expression profiles for a set of breast tumors.

  28. 28 GSE37181 收集123例人类乳腺癌原发肿瘤样本,按是否发生远处转移(distant metastasis 0-none为0,发生转移为1)分组,采用微阵列技术检测基因表达,比较两组间IFN诱导基因相关转录特征差异。 人源 · 123 例 · GPL6884 · 2014/05/01

    设计收集123例人类乳腺癌原发肿瘤样本,按是否发生远处转移(distant metastasis 0-none为0,发生转移为1)分组,采用微阵列技术检测基因表达,比较两组间IFN诱导基因相关转录特征差异。

    摘要We identified and validated the pivotal role for a metagene containing IFN-induced genes in association to higher metastatic potential as a function of the specific molecular subtype

  29. 29 GSE19615 对115例人类乳腺肿瘤组织进行Affymetrix U133plus2芯片分析,研究对象为具有8q22拷贝数增益的肿瘤样本,检测方式为基因表达分析,主要比较8q22区域基因表达与肿瘤复发的相关性。 人源 · 115 例 · GPL570 · 2010/01/05

    设计对115例人类乳腺肿瘤组织进行Affymetrix U133plus2芯片分析,研究对象为具有8q22拷贝数增益的肿瘤样本,检测方式为基因表达分析,主要比较8q22区域基因表达与肿瘤复发的相关性。

    摘要Integrated DNA and expression array analysis in primary human breast tumors identified chromosome 8q22 copy number gain and a suite of over-expressed genes in this region highly relevant to subsequent recurrence. 8q copy gain is associated with increased risk of distant metastasis despite adjuvant chemotherapy and multiple genes from 8q22 are overexpressed and have pleiotropic effects, contributing to tumor growth, survival, and reduced killing of tumor cell by chemotherapy.

  30. 30 GSE208102 对原发性腔面乳腺癌患者的FFPE肿瘤样本进行基因表达谱分析,根据局部复发状态(EARLY、INTERMEDIATE、LATE)分组,比较不同复发阶段的基因表达差异。检测采用微阵列平台(GPL23126)并使用sst-RMA算法处理CEL文件,样本量为111个FFPE肿瘤样本。 人源 · 111 例 · GPL23126 · 2023/09/15

    设计对原发性腔面乳腺癌患者的FFPE肿瘤样本进行基因表达谱分析,根据局部复发状态(EARLY、INTERMEDIATE、LATE)分组,比较不同复发阶段的基因表达差异。检测采用微阵列平台(GPL23126)并使用sst-RMA算法处理CEL文件,样本量为111个FFPE肿瘤样本。

    摘要This SuperSeries is composed of the SubSeries listed below.

  31. 31 GSE146558 对台湾地区乳腺癌患者肿瘤组织进行基因表达分析,根据微钙化状态(存在或无)及临床特征(如复发状态、生存时间)分组,比较不同组别间的基因表达差异。 人源 · 109 例 · GPL570 · 2020/10/05

    设计对台湾地区乳腺癌患者肿瘤组织进行基因表达分析,根据微钙化状态(存在或无)及临床特征(如复发状态、生存时间)分组,比较不同组别间的基因表达差异。

    摘要Microcalcification is one of the most common radiological and pathological features of breast ductal carcinoma in situ (DCIS), and to a lesser extent, invasive ductal carcinoma. We evaluated transcriptional profiles associated with ectopic mammary mineralization. We evaluated the transcriptional profiles associated with breast cancer microcalcification for Taiwanese breast cancer and a gene expression signature was derived.

  32. 32 GSE189371 对乳腺癌患者进行总RNA测序,样本根据复发状态分组,比较不同复发状态下的RNA表达特征。 人源 · 96 例 · GPL29480 · 2023/11/21

    设计对乳腺癌患者进行总RNA测序,样本根据复发状态分组,比较不同复发状态下的RNA表达特征。

    摘要The key radiomic features were found to vary after neoadjuvant chemotherapy. Moreover, lncRNAs were discovered to be significantly correlated with radiomics and recurrence-free survival (RFS). The findings indicate that the radiomic signature can be conveniently used for individualized prediction of RFS and that radiomics is associated with lncRNAs in breast cancer.

  33. 33 GSE58984 对HER2阳性早期乳腺癌患者进行基因表达分析,采集其组织样本并采用adjuvant trastuzumab治疗,通过基因表达谱检测了解治疗对基因表达的影响。 人源 · 94 例 · GPL570 · 2016/12/31

    设计对HER2阳性早期乳腺癌患者进行基因表达分析,采集其组织样本并采用adjuvant trastuzumab治疗,通过基因表达谱检测了解治疗对基因表达的影响。

    摘要The human epidermal growth factor receptor 2 (HER2) gene encodes a tyrosine kinase receptor that controls important signal transduction pathways in breast cancer. Amplification and overexpression of the HER2 gene occurs in approximately 20% of breast cancers and is associated with an aggressive clinical phenotype. Trastuzumab, a humanized monoclonal antibody that targets HER2 showed exceptional efficacy in the treatment of breast cancer. In the adjuvant treatment of breast cancer patients, five randomized trials showed significant benefit of trastuzumab, with a reduction in the rate of recurrence of approximately 50% and improvement in the rate of survival of approximately 30%. In the current study, positive early stage breast cancer samples treated with adjuvant trastuzumab provided by institute Jules Bordet (IJB) and KUL. Gene expression and clinical outcome data were available. to better understand the genetic regulations and effects of the trastuzumab, we profile the the genes expression of positive early stage breast cancer samples treated with adjuvant trastuzumab.

  34. 34 GSE291966 收集75名三阴性乳腺癌患者肿瘤样本建立92个原位患者来源异种移植模型,包含治疗前、治疗中、治疗后及复发阶段的纵向样本和转移性样本。采用RNA-Seq技术对肿瘤组织进行转录组分析,比较不同时间点及转移状态下的基因表达特征。 人源 · 92 例 · GPL11154;20301 · 2025/07/23

    设计收集75名三阴性乳腺癌患者肿瘤样本建立92个原位患者来源异种移植模型,包含治疗前、治疗中、治疗后及复发阶段的纵向样本和转移性样本。采用RNA-Seq技术对肿瘤组织进行转录组分析,比较不同时间点及转移状态下的基因表达特征。

    摘要Triple negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity characteristic of TNBC. To that end, we established a biobank of 92 orthotopic patient-derived xenograft (PDX) models of TNBC from the tumors of 75 patients enrolled in the ARTEMIS clinical trial (NCT02276443) at MD Anderson Cancer Center, including 12 longitudinal sets generated from serial patient biopsies collected throughout NACT and from metastatic disease. Models were established from both chemosensitive and chemoresistant tumors and nearly 30% of PDX models were capable of lung metastasis. Comprehensive molecular profiling demonstrated conservation of genomes and transcriptomes between patient and corresponding PDX tumors, with representation of all major transcriptional subtypes. Transcriptional changes observed in the longitudinal PDX models highlight dysregulation in pathways associated with DNA integrity, extracellular matrix interactions, the ubiquitin-proteasome system, epigenetics, and inflammatory signaling. These alterations reveal a complex network of adaptations associated with chemoresistance. This PDX biobank provides a valuable resource for tackling the most pressing issues facing the clinical management of TNBC, namely chemoresistance and metastasis.

  35. 35 GSE192341 本研究收集了87例接受新辅助化疗前的乳腺癌活检样本,采用RNA测序技术分析其基因表达谱,以探讨新辅助治疗反应相关机制。样本来自人类乳腺组织,未提及混池方式,未明确分组处理条件,主要比较不同亚型患者治疗反应与生存数据。 人源 · 87 例 · GPL11154 · 2021/12/28

    设计本研究收集了87例接受新辅助化疗前的乳腺癌活检样本,采用RNA测序技术分析其基因表达谱,以探讨新辅助治疗反应相关机制。样本来自人类乳腺组织,未提及混池方式,未明确分组处理条件,主要比较不同亚型患者治疗反应与生存数据。

    摘要When locally advanced breast cancer is treated with neoadjuvant chemotherapy, the recurrence risk is significantly higher if no complete pathologic response is achieved. Identification of the underlying resistance mechanisms is essential to select treatments with maximal efficacy and minimal toxicity. Here we employed gene expression profiles derived from 317 HER2-negative treatment-naïve breast cancer biopsies of patients who underwent neoadjuvant chemotherapy, deep whole exome and RNA-sequencing profiles of 22 matched pre- and post-treatment tumors, and treatment outcome data to identifiy biomarkers of response and resistance mechanims. Molecular profiling of treatment-naïve breast cancer samples revealed that expression levels of proliferation, immune response and extracellular matrix (ECM) organization combined predict response to chemotherapy. Triple negative patients with high proliferation, high immune response and low ECM expression had a significantly better treatment response and survival benefit (HR 0.29, 95% CI 0.10-0.85; p=0.02), while in ER+ patients the opposite was seen (HR 4.73, 95% CI 1.51-14.8; 0=0.008). The characterization of paired pre-and post-treatment samples revealed that aberrations of known cancer genes were either only present in the pre-treatmane sample (CDKN1B) or in the post-treatment sample(TP53, APC, CTNNB1). Proliferation-associated genes were frequently down-regulated in post-treatment ER+ tumors, but not in triple negative tumors. Genes involved in ECM were upregulated in the majority of post-chemotherapy samples. Genomic and transcriptomic differences between pre- and post-chemotherapy samples are common and may reveal potential mechanisms of therapy resistance. Our results show a wide range of distinct, but related mechanisms, with a prominent role for proliferation- and ECM-related genes.

  36. 36 GSE27531 研究对象为接受局部区域治疗且淋巴结阴性的女性乳腺癌患者,其样本分为同步双侧癌(18例)、异时双侧癌(11例)和局部复发癌(10例)三组。采集临床乳腺癌组织样本进行基因表达分析,采用微阵列平台 GPL6884,检测总 RNA 表达特征,比较不同肿瘤类型间的基因表达差异。 人源 · 82 例 · GPL6884 · 2018/02/13

    设计研究对象为接受局部区域治疗且淋巴结阴性的女性乳腺癌患者,其样本分为同步双侧癌(18例)、异时双侧癌(11例)和局部复发癌(10例)三组。采集临床乳腺癌组织样本进行基因表达分析,采用微阵列平台 GPL6884,检测总 RNA 表达特征,比较不同肿瘤类型间的基因表达差异。

    摘要Dissecting time-related from genetic-related gene expression variability in the bilateral breast cancer model.

  37. 37 GSE48390 研究基于台湾女性乳腺癌组织样本,采用array CGH和基因表达微阵列技术检测基因拷贝数变异与差异表达模式。从同时使用两种平台的21个样本中识别出具有协同变化的基因,用于构建与临床ER状态、HER2状态及无病生存相关的风险预测模型。通过比较高风险组与低风险组的生存时间差异,发现风险评分在复发、转移或死亡患者中显著高于无复发个体。分组依据包括ER阳性/阴性、HER2正常/过表达、hu306分类(Luminal A、Normal breast-like、HER2-enriched、Luminal B、Basal-like subtype)及预测风险等级。 人源 · 81 例 · GPL570 · 2014/01/07

    设计研究基于台湾女性乳腺癌组织样本,采用array CGH和基因表达微阵列技术检测基因拷贝数变异与差异表达模式。从同时使用两种平台的21个样本中识别出具有协同变化的基因,用于构建与临床ER状态、HER2状态及无病生存相关的风险预测模型。通过比较高风险组与低风险组的生存时间差异,发现风险评分在复发、转移或死亡患者中显著高于无复发个体。分组依据包括ER阳性/阴性、HER2正常/过表达、hu306分类(Luminal A、Normal breast-like、HER2-enriched、Luminal B、Basal-like subtype)及预测风险等级。

    摘要The interplay between copy number variation (CNV) and differential gene expression may be able to shed light on molecular process underlying breast cancer and lead to the discovery of cancer-related genes. In the current study, genes concurrently identified in array comparative genomic hybridization (CGH) and gene expression microarrays were used to derive gene signatures for Han Chinese breast cancers. We performed 23 array CGHs and 81 gene expression microarrays in breast cancer samples from Taiwanese women. Genes with coherent patterns of both CNV and differential gene expression were identified from the 21 samples assayed using both platforms. We used these genes to derive signatures associated with clinical ER and HER2 status and disease-free survival. Distributions of signature genes were strongly associated with chromosomal location: chromosome 16 for ER and 17 for HER2. A breast cancer risk predictive model was built based on the first supervised principal component from 16 genes (RCAN3, MCOLN2, DENND2D, RWDD3, ZMYM6, CAPZA1, GPR18, WARS2, TRIM45, SCRN1, CSNK1E, HBXIP, CSDE1, MRPL20, IKZF1, and COL20A1), and distinct survival patterns were observed between the high- and low-risk groups from the combined dataset of 408 microarrays. The risk score was significantly higher in breast cancer patients with recurrence, metastasis, or mortality than in relapse-free individuals (0.241 versus 0, P<0.001). The concurrent gene risk predictive model remained discriminative across distinct clinical ER and HER2 statuses in subgroup analysis. We conclude that parallel analysis of CGH and microarray data, in conjunction with known gene expression patterns, can be used to identify biomarkers with prognostic values in breast cancer.

  38. 38 GSE285299 对接受内分泌治疗的 HER2- ER+乳腺癌患者进行基因表达分析,根据是否复发(包括局部区域复发与远处复发)分为复发组与非复发组,采用 NanoString nCounter® Custom CodeSet 进行 mRNAseq 测定,比较两组间基因表达差异。样本为手术病理档案中 ER+比例超过 10% 的 FFPE 组织,研究对象为乳腺癌原发患者。 人源 · 80 例 · GPL35249 · 2024/12/25

    设计对接受内分泌治疗的 HER2- ER+乳腺癌患者进行基因表达分析,根据是否复发(包括局部区域复发与远处复发)分为复发组与非复发组,采用 NanoString nCounter® Custom CodeSet 进行 mRNAseq 测定,比较两组间基因表达差异。样本为手术病理档案中 ER+比例超过 10% 的 FFPE 组织,研究对象为乳腺癌原发患者。

    摘要Gene expression analysis to study early-stage estrogen receptor-positive breast cancer patient associated with endocrine therapy resistance.

  39. 39 GSE9195 对接受他莫昔芬治疗的雌性乳腺癌患者进行分子特征分析,采集其原发性肿瘤样本进行基因表达谱检测,通过构建包含 181 个基因的分类器,将样本分为两个不同的预后组,比较其临床结局差异。 人源 · 77 例 · GPL570 · 2008/05/07

    设计对接受他莫昔芬治疗的雌性乳腺癌患者进行分子特征分析,采集其原发性肿瘤样本进行基因表达谱检测,通过构建包含 181 个基因的分类器,将样本分为两个不同的预后组,比较其临床结局差异。

    摘要Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen treatment. New prognostic biomarkers and further biological understanding of tamoxifen resistance are required. We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. We used clusters of highly correlated genes to develop our predictor to facilitate both signature stability and biological interpretation. Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings. Results: We developed a gene classifier consisting of 181 genes belonging to 13 biological clusters. In the independent set of adjuvantly-treated samples, it was able to define two distinct prognostic groups (HR 2.01 95%CI: 1.29-3.13; p=0.002). Six of the 13 gene clusters represented pathways involved in cell cycle and proliferation. In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components suggesting a cellular inflammatory mechanism was significantly predictive of response. Conclusions: We have developed a gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients. Whilst our study emphasizes the important role of proliferation genes in prognosis, our approach proposes other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxifen. Keywords: disease state analysis

  40. 40 GSE10884 对乳腺癌复发的bulk RNA样本与参考样本进行比较,通过DNA微阵列检测RB1基因表达水平,分析Basal-like和Luminal B亚型肿瘤中RB1基因缺失(LOH)与基因表达之间的关系。 人源 · 66 例 · GPL887;1390;885;5325 · 2008/09/18

    设计对乳腺癌复发的bulk RNA样本与参考样本进行比较,通过DNA微阵列检测RB1基因表达水平,分析Basal-like和Luminal B亚型肿瘤中RB1基因缺失(LOH)与基因表达之间的关系。

    摘要Breast cancers can be classified using whole genome expression into distinct subtypes that show differences in patient prognosis. One of these groups, the basal-like carcinomas, are poorly differentiated, highly metastatic, and genomically unstable. These tumors also contain specific genetic alterations with one example being frequent p53 mutations. The loss of the tumor suppressor gene encoded by the retinoblastoma (RB1) locus is a well-characterized occurrence in many tumor types, however, its role in breast cancer is less clear with many reports demonstrating a Loss of Heterozygosity (LOH) that does not correlate with loss of RB1 protein expression. Here we report that LOH of the RB1 locus was observed at a high frequency in basal-like and luminal B tumors. These tumors also concurrently have low expression of RB1 mRNA as assessed by DNA microarray. As in previous reports, we also did not see a significant correlation between RB1 LOH and protein expression as measured by immunohistochemistry (IHC). p16INK4a, however, was highly expressed both by microarray and IHC, in basal-like tumors only presumably due to a previously reported feedback loop caused by RB1 loss. These results suggest that the functional loss of RB1 is a common event in the progression of basal-like and luminal B breast tumors, which may play a key role in dictating therapeutic responses Keywords: reference x sample

  41. 41 GSE329391 研究对象为乳腺癌复发的肿瘤组织,测量了肿瘤内雄激素(A4)和雌激素(estrone)水平,并对肿瘤组织进行RNA提取和RNA测序。根据A4水平将样本分为高A4和低A4组,比较两组间的差异基因(DEGs)及通路,以揭示A4依赖的分子特征与乳腺癌预后的关系。 人源 · 61 例 · GPL24676 · 2026/09/04

    设计研究对象为乳腺癌复发的肿瘤组织,测量了肿瘤内雄激素(A4)和雌激素(estrone)水平,并对肿瘤组织进行RNA提取和RNA测序。根据A4水平将样本分为高A4和低A4组,比较两组间的差异基因(DEGs)及通路,以揭示A4依赖的分子特征与乳腺癌预后的关系。

    摘要The role of androgens in breast cancer (BC) was defined by correlating circulating androgens to clinical variables. Considering that intratumoral hormonal milieu is the critical determinant of BC characteristics, correlating intratumoral, androgens and their downstream transcriptome, a measure of free unbound androgen function, will provide clarity on androgen action in BC. Preclinical studies have shown that androgens and their receptor, androgen receptor (AR), have complex function in BC functioning as tumor suppressor in estrogen receptor (ER)-positive BC and oncogene in triple negative BC (TNBC). To obtain clarity on the role of androgens in BC, we measured intratumoral androgens and transcriptome in patient specimens. Intratumoral androstenedione (A4), but not dehydroepiandrosterone nor testosterone, from 62 BC specimens correlated with 1388 genes. A4-correlated genes classified patients into low, intermediate, and high A4 levels. A4-high patients had lower tumor cell proliferation, stage, and grade, and longer survival. A4-low patients’ tumors belonged to TNBC subtype and comprised of African American women. High intratumoral A4 levels extended the survival of ER+ve patients. These results were verified using TCGA and an independent clinical cohort. Using machine learning, we refined 1388 genes to a robust 90-gene A4-driven predictive signature. This signature strongly correlated with A4 levels and accurately predicted important clinical properties including tumor aggressiveness and survival outcomes. Collectively, we have discovered a tumor suppressor role for androgens, especially A4, in BC and identified a 90-gene A4 signature that offers a powerful tool for predicting A4 levels and related prognostic markers, which are otherwise challenging to assess.

  42. 42 GSE207847 对术后不同时间点发生局部复发的原发性腔面型乳腺癌患者FFPE样本进行基因表达分析,按复发时间分为早期(<2年)、中期(>2至<5年)和晚期(<5年)三组,采用Clariom D平台检测总RNA表达谱,比较各复发时间点样本的基因表达差异。 人源 · 60 例 · GPL23126 · 2023/09/15

    设计对术后不同时间点发生局部复发的原发性腔面型乳腺癌患者FFPE样本进行基因表达分析,按复发时间分为早期(<2年)、中期(>2至<5年)和晚期(<5年)三组,采用Clariom D平台检测总RNA表达谱,比较各复发时间点样本的基因表达差异。

    摘要We aimed at finding a gene signature able to discriminate patients who had a loco-regional recurrence either at early time after surgery or late (< 2 yrs, early; >2 and <5 yrs, intermediate; < 5 yrs, late)

  43. 43 GSE22049 对人类乳腺肿瘤样本进行批量RNA测序,分析miR-30c与化疗耐药性、TWF1和IL-11表达的关系,比较不同乳腺肿瘤亚型(如HER2+/ER-、Basal-like、LuminalA、LuminalB、Normal-like等)的复发无病生存期(RFS)和总生存期(OS)数据,研究miR-30c对化疗耐药性的调控作用。 人源 · 60 例 · GPL885;887;1390;5325;8274;7504 · 2013/01/18

    设计对人类乳腺肿瘤样本进行批量RNA测序,分析miR-30c与化疗耐药性、TWF1和IL-11表达的关系,比较不同乳腺肿瘤亚型(如HER2+/ER-、Basal-like、LuminalA、LuminalB、Normal-like等)的复发无病生存期(RFS)和总生存期(OS)数据,研究miR-30c对化疗耐药性的调控作用。

    摘要Chemotherapy resistance frequently drives tumor progression. However, the underlying molecular mechanisms are poorly characterized. Epithelial-to-mesenchymal transition (EMT) has been shown to correlate with therapy resistance, but the functional link and signaling pathways remain to be elucidated. We report here that miR-30c, a human breast tumor prognostic marker, plays a pivotal role in chemo-resistance by a direct targeting of the actin-transporter TWF1, which promotes EMT. An IL-6 family member, IL-11 was identified as a secondary target of TWF1 in the miR-30c signaling pathway. Expression of miR-30c inversely correlated with IL-11 expression in clinical tumors and IL-11 correlated with relapse-free survival in breast cancer patients. Identification of a novel miRNA-mediated pathway that regulates chemo-resistance in breast cancer will facilitate the development of new management strategies.

  44. 44 GSE303203 对TNBC患者来源异种移植模型(PDX)进行基因表达分析,比较不同化疗药物(Capecitabine、Cisplatin、Anthracyclines)处理后残留肿瘤与复发肿瘤的转录组差异,同时设置未处理的化疗初治肿瘤作为对照。采用Affymetrix平台检测总RNA表达,分析药物耐受性细胞在治疗后复发时是否回归治疗前状态。 人源 · 59 例 · GPL570 · 2025/09/22

    设计对TNBC患者来源异种移植模型(PDX)进行基因表达分析,比较不同化疗药物(Capecitabine、Cisplatin、Anthracyclines)处理后残留肿瘤与复发肿瘤的转录组差异,同时设置未处理的化疗初治肿瘤作为对照。采用Affymetrix平台检测总RNA表达,分析药物耐受性细胞在治疗后复发时是否回归治疗前状态。

    摘要Acquisition of resistance to anti-cancer therapies is a multistep process, which initiates with the survival of drug tolerant persister cells. Understanding the mechanisms driving the emergence of drug tolerant persister cells remains challenging, primarily because of their limited accessibility in patients. Here, using multiple patient-derived models to isolate persister cells, we show these cells are transcriptionally plastic in vivo and return to a common treatment-naïve like state upon relapse, regardless of the treatment they have been exposed to. We reveal hallmarks of the persister state in TNBC across treatment modalities: high expression of basal keratins together with activation of a stress response and inflammation pathways. HER2+ breast and lunger cancer cells also activate these hallmarks of drug tolerance in response to targeted therapies. Leveraging gene regulatory networks, we identify AP-1, NFKB and IRF/STAT as the key drivers of this hallmark persister state. As a proof of concept, we show that FOSL1 - an AP-1 member - is sufficient to drive cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 have a decreased ability to reach the persister state. By defining hallmarks of drug persistence to multiple therapies of the standard of care in TNBC, our study provides a resource to design novel combination therapeutic strategies to limit resistance. All datasets produced for this study are available and deposited on GEO at : GSE280454, GSE280455, GSE303200, GSE303201 & GSE303203

  45. 45 GSE4913 对接受乳腺保乳治疗的乳腺癌患者原发肿瘤进行基因表达谱分析,其中19例患者出现局部复发,31例患者治疗后11年无复发。对9对原发肿瘤与局部复发样本进行配对分析,所有样本与超过100例乳腺癌样本的混合RNA参考共同杂交,采用cDNA微阵列技术检测总RNA表达模式,比较复发组与对照组原发肿瘤的基因表达差异及配对样本间的相似性。 人源 · 59 例 · GPL3558 · 2006/09/24

    设计对接受乳腺保乳治疗的乳腺癌患者原发肿瘤进行基因表达谱分析,其中19例患者出现局部复发,31例患者治疗后11年无复发。对9对原发肿瘤与局部复发样本进行配对分析,所有样本与超过100例乳腺癌样本的混合RNA参考共同杂交,采用cDNA微阵列技术检测总RNA表达模式,比较复发组与对照组原发肿瘤的基因表达差异及配对样本间的相似性。

    摘要Purpose: Several risk factors for local recurrence of breast cancer after breast conserving therapy (BCT) have been identified. The identification of additional risk factors would be very useful in guiding optimal therapy and also improve understanding of the mechanisms underlying local recurrence. We used cDNA microarray analysis to identify gene expression profiles associated with local recurrence. Experimental Design: Using 18K cDNA microarrays, gene expression profiles were obtained from 50 patients who underwent BCT. Of these 50 patients 19 developed a local recurrence; the remaining 31 patients were selected as controls as they were free of local recurrence at least 11 years after treatment. For 9/19 patients also the local recurrence was available for gene expression profiling. Unsupervised and supervised methods of classification were used to separate patients in groups corresponding to disease outcome and to study the overall gene expression pattern of primary tumors and their recurrences. Results: Hierarchical clustering of patients did not show any grouping reflecting local recurrence status. Supervised analysis revealed no significant set of genes that was able to distinguish recurring tumors from non-recurring tumors. Paired-data analysis of primary tumors and local recurrences showed a remarkable similarity in gene expression profile between primary tumors and their recurrences. Conclusions: No significant differences in gene expression between primary breast cancer tumors in patients with or without local recurrence after breast conserving therapy were identified. Furthermore, analyses of primary tumors and local recurrences show a preservation of the overall gene expression pattern in the local recurrence, even after radiotherapy. Keywords: gene expression profiling

  46. 46 GSE233909 将56例日本乳腺癌患者的手术获取的新鲜冷冻肿瘤样本进行总RNA提取,采用Affymetrix microarrays检测基因表达,比较95(GC)与21(GC)在预测复发风险中的分类效能,并评估其联合应用。 人源 · 56 例 · GPL570 · 2023/06/03

    设计将56例日本乳腺癌患者的手术获取的新鲜冷冻肿瘤样本进行总RNA提取,采用Affymetrix microarrays检测基因表达,比较95(GC)与21(GC)在预测复发风险中的分类效能,并评估其联合应用。

    摘要The aim of this study was to validate the efficacy of 95(GC) and compare it with that of 21(GC) (Oncotype DX) as well as to evaluate the combination of 95(GC) and 21(GC). DNA microarray data (gene expression) of ER-positive and node-negative breast cancer patients (n = 459) treated with adjuvant hormone therapy alone were classified with 95(GC) and 21(GC) (Recurrence Online at http://www.recurrenceonline.com/ ). 95(GC) classified the 459 patients into low-risk (n = 285; 10 year relapse-free survival: 88.8 %) and high-risk groups (n = 174; 70.6 %) (P = 5.5e-10), and 21(GC) into low-risk group (n = 286; 89.3 %), intermediate-risk (n = 81; 75.7 %), and high-risk (n = 92; 64.7 %) groups (P = 2.9e-10). The combination of 95(GC) and 21(GC) classified them into low-risk (n = 324; 88.9 %) and high-risk (n = 135; 65.0 %) groups (P = 5.9e-14). This DATA set: J02 is 56 of the above 459 cases from Japan who were assayed after the J01 DATA set. *Note: This old data has been updated multiple times by others. Then, there are some differences from the original 2013 paper and unclear points still remain. Therefore, do not use it for formal analysis aimed at public insurance coverage etc. This is for research purposes only. Please cite this paper when writing a new paper. PMID: 23884597 DOI: 10.1007/s10549-013-2640-9

  47. 47 GSE55348 对HER2阳性乳腺癌患者接受辅助曲妥珠单抗治疗后的福尔马林固定石蜡包埋组织进行基因表达分析,比较复发与未复发病例的基因表达差异,共53例样本,分为23例复发和30例未复发。 人源 · 53 例 · GPL14951 · 2015/10/19

    设计对HER2阳性乳腺癌患者接受辅助曲妥珠单抗治疗后的福尔马林固定石蜡包埋组织进行基因表达分析,比较复发与未复发病例的基因表达差异,共53例样本,分为23例复发和30例未复发。

    摘要Trastuzumab, a humanized monoclonal antibody directed to the HER2 protein, is the standard-of-care treatment for patients with HER2 positive breast cancer, reducing the risk of relapse and death in patients. Nonetheless, some patients relapse after treatment, underscoring the need to identify patients for whom chemotherapy + trastuzumab is adequate versus patients requiring additional drugs. To search for genes predictive of relapse in HER2-positive breast carcinoma patients treated with adjuvant trastuzumab, we conducted gene expression profiling analysis in 53 cases treated in the clinic with doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) and trastuzumab.

  48. 48 GSE208101 对术后不同时间点(早期<2年,中期>2至<5年,晚期<5年)的局部复发乳腺癌患者,采集FFPE样本的总RNA,使用Clariom D平台进行基因表达分析,比较各时间点的基因表达差异。 人源 · 51 例 · GPL23126 · 2023/09/15

    设计对术后不同时间点(早期<2年,中期>2至<5年,晚期<5年)的局部复发乳腺癌患者,采集FFPE样本的总RNA,使用Clariom D平台进行基因表达分析,比较各时间点的基因表达差异。

    摘要We aimed at finding a gene signature able to discriminate patients who had a loco-regional recurrence either at early time after surgery or late (< 2 yrs, early; >2 and <5 yrs, intermediate; < 5 yrs, late)

  49. 49 GSE183231 对淋巴结阳性乳腺癌患者的福尔马林固定石蜡包埋组织进行基因表达分析,比较ER+和ER-肿瘤组织中复发与非复发样本的基因表达差异。研究对象为接受他莫昔芬治疗并伴随淋巴细胞浸润的乳腺癌患者,所有样本均经过化疗处理,复发组包含25例FFPE样本,非复发组包含12例FFPE样本。 人源 · 37 例 · GPL23126 · 2021/09/04

    设计对淋巴结阳性乳腺癌患者的福尔马林固定石蜡包埋组织进行基因表达分析,比较ER+和ER-肿瘤组织中复发与非复发样本的基因表达差异。研究对象为接受他莫昔芬治疗并伴随淋巴细胞浸润的乳腺癌患者,所有样本均经过化疗处理,复发组包含25例FFPE样本,非复发组包含12例FFPE样本。

    摘要Several studies provide genes expression characteristic correlated to recurrence in breast cancer patients with lymph node negative. However few reports mentioned about the gene expression file in patients with lymph node metastasis confirmed during surgery, of which the cumulative incidences of relapse are more than 50%.

  50. 50 GSE88847 对37例乳腺癌复发患者的肿瘤组织进行基因表达分析,采用Affymetrix Human Gene 1.0 ST Array检测,未明确分组或处理条件。 人源 · 37 例 · GPL20171 · 2019/02/22

    设计对37例乳腺癌复发患者的肿瘤组织进行基因表达分析,采用Affymetrix Human Gene 1.0 ST Array检测,未明确分组或处理条件。

    摘要Engaging the immune system promises to be key for optimal cancer therapy, especially in hard-to-treat disease such as triple-negative breast cancer (TNBC). However, the immune microenvironment remains poorly understood. Using gene expression based on laser capture microdissection, we identify three distinct tumor microenvironments associated with CD8+ T cell localization patterns and outcome in TNBC. An immunoreactive microenvironment is defined by granzyme B-positive CD8+ T cell infiltration, a type I interferon signature, tumor expression of PD-L1 and good outcome. In contrast, tumors with an immune-cold microenvironment display restriction of CD8+ T cells to tumor margins, elevated tumor expression of the immunosuppressive marker B7-H4, a signature of desmoplastic stroma and poor outcome. A third distinct immunomodulatory microenvironment associated with poor outcome is enriched for IL-17-producing cells and neutrophils, as well as stroma-restricted localisation of CD8+ T cells. These distinct immune microenvironments have implications for TNBC patient stratification for current and future therapies.

  51. 51 GSE15363 从IDC乳腺癌病例中激光捕获显微切割分离肿瘤相关乳腺血管组织,提取总RNA进行基因表达分析,比较复发与非复发患者的基因表达差异。 人源 · 32 例 · GPL1708 · 2010/09/19

    设计从IDC乳腺癌病例中激光捕获显微切割分离肿瘤相关乳腺血管组织,提取总RNA进行基因表达分析,比较复发与非复发患者的基因表达差异。

    摘要Tumor-associated breast vasculature was laser-cappture microdissected from IDC breast cancer cases. The goal of the study was to characterize the heterogeneity of breast tumor-associated vasculature and identify gene expression signatures predictive of clinical outcome.

  52. 52 GSE156873 对28例早期乳腺癌女性患者(14例局部复发与14例匹配对照)的手术切除乳腺肿瘤样本进行微阵列分析,比较两组间基因表达差异。研究采用FFPE组织样本,通过RMA算法处理Affymetrix平台数据,未涉及混池或重复处理。 人源 · 28 例 · GPL17586 · 2021/01/01

    设计对28例早期乳腺癌女性患者(14例局部复发与14例匹配对照)的手术切除乳腺肿瘤样本进行微阵列分析,比较两组间基因表达差异。研究采用FFPE组织样本,通过RMA算法处理Affymetrix平台数据,未涉及混池或重复处理。

    摘要The current analysis was a two phase study. The first step of the pilot phase comprised an in-silico search for potential target molecules in five different databases. The second step was a screen for potential targets in 28 patients (14 with local relapse and 14 matched controls) by means of microarray technology. The combined results formed the basis for the validation phase in an independent set of 53 patients performed with droplet digital PCR (ddPCR).

  53. 53 GSE128600 对ER阳性乳腺癌患者的原发肿瘤组织进行微阵列分析,根据复发状态分为复发组与非复发组,各组样本数按总单位数与组数估计为12个,比较两组间基因表达差异。 人源 · 24 例 · GPL17077 · 2019/12/31

    设计对ER阳性乳腺癌患者的原发肿瘤组织进行微阵列分析,根据复发状态分为复发组与非复发组,各组样本数按总单位数与组数估计为12个,比较两组间基因表达差异。

    摘要Long non-coding RNA NR2F1 antisense RNA1 (lncRNA NR2F1-AS1) was identified as the main candidate associated to late recurrence in ER-positive breast cancer clinical samples. Gain-of-function of NR2F1-AS1 induced the expression of dormancy-inducers BMP4 and DEC2, and upregulated pluripotency markers NANOG and OCT4. Representative pathways entailed to metastatic events such as HER2/Neu, hypoxia, EMT and inflammatory-response were also found enriched.

  54. 54 GSE189389 对晚期复发(LSR)的ER+乳腺癌患者的转移性乳腺组织样本进行RNA测序,分析融合转录本的存在。 人源 · 24 例 · GPL16791 · 2021/11/23

    设计对晚期复发(LSR)的ER+乳腺癌患者的转移性乳腺组织样本进行RNA测序,分析融合转录本的存在。

    摘要RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. We performed sequencing on RNA extracted from metastatic biopsy samples from patients with ER+ breast cancer to assess the presence of fusion transcripts.

  55. 55 GSE9662 对导管浸润性乳腺癌患者的肿瘤样本进行基因表达分析,将术后72个月内复发的高风险组与72个月无复发的低风险组各30例样本分为6个RNA池(每池5个样本),采用Affymetrix寡核苷酸微阵列(GPL96)检测,并在技术重复中进行两次实验。通过比较两组间的基因表达差异,识别与复发风险相关的基因。 人源 · 24 例 · GPL96 · 2008/11/19

    设计对导管浸润性乳腺癌患者的肿瘤样本进行基因表达分析,将术后72个月内复发的高风险组与72个月无复发的低风险组各30例样本分为6个RNA池(每池5个样本),采用Affymetrix寡核苷酸微阵列(GPL96)检测,并在技术重复中进行两次实验。通过比较两组间的基因表达差异,识别与复发风险相关的基因。

    摘要To identify a group of genes, characteristic of a single neoplasia and determinant for the risk to relapse, we have performed gene expression analysis of ductal breast carcinoma samples using Affymetrix oligonucletide microarray (HU133A). Biopses from 60 patients, 30 good prognosis (desease free from six to ten years after surgical treatment) and 30 poor prognosis, have been analyzed. From each group we have created six homogeneous pools to show, during the analysis, only genes expressed in a greatly different way. A reduced number of cases has been used to avoid dilution of genes expressed only in few samples. Analysis have identified 77 candidate genes with a specific ontological distribution that contained some genes that were linked to breast cancer by previous studies. Microarray results validation has been performed by real-time PCR analysis on 127 single cases of breast cancer. Gene function study and literature data allow to define our candidate genes as potential markers of prognosis. Keywords: Breast cancer gene expression analysis

  56. 56 GSE345048 对16名复发或转移性炎症性乳腺癌患者的肿瘤活检样本进行外显子捕获RNA测序,包括7对基线与治疗期间的配对样本。样本分为ACE组(接受阿替利珠单抗、科比美替尼和厄立布林治疗)和AE组(仅接受阿替利珠单抗和厄立布林治疗),采集组织包括乳腺、胸部皮肤、肝脏、腹膜后和纵隔。检测方式为RNA-Seq,采用不同捕获试剂盒分三批进行,主要比较ACE组与AE组的基因表达差异。 人源 · 23 例 · GPL24676 · 2026/10/18

    设计对16名复发或转移性炎症性乳腺癌患者的肿瘤活检样本进行外显子捕获RNA测序,包括7对基线与治疗期间的配对样本。样本分为ACE组(接受阿替利珠单抗、科比美替尼和厄立布林治疗)和AE组(仅接受阿替利珠单抗和厄立布林治疗),采集组织包括乳腺、胸部皮肤、肝脏、腹膜后和纵隔。检测方式为RNA-Seq,采用不同捕获试剂盒分三批进行,主要比较ACE组与AE组的基因表达差异。

    摘要Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer and lacks predictive biomarkers for immune-checkpoint-based combinations. In the phase Ib/II 2016-0890 trial (NCT03202316), patients with recurrent or metastatic IBC received atezolizumab, cobimetinib and eribulin (ACE, cohort 1) or atezolizumab and eribulin (AE, cohort 2). Fresh-frozen tumor biopsies were collected at baseline and, where feasible, on treatment, and profiled by exome-capture RNA sequencing. This Series provides gene-level expression matrices for 23 tumor libraries from 16 patients (7 patients with paired baseline / on-treatment biopsies). Transcriptomic analysis of these samples separated durable clinical benefit from non-benefit and implicated interferon-stimulated gene modules, stromal/immune-exclusion programs and KRAS-linked metabolic circuits as correlates of resistance. Matched whole-exome sequencing and the raw sequence data for this cohort are deposited under controlled access in dbGaP (phs004886).

  57. 57 GSE214789 对14例原发性乳腺肿瘤样本(n=14)进行RNA测序,比较7例对治疗反应良好的患者与7例内分泌治疗后疾病复发患者的转录组差异。 人源 · 14 例 · GPL20301 · 2023/05/16

    设计对14例原发性乳腺肿瘤样本(n=14)进行RNA测序,比较7例对治疗反应良好的患者与7例内分泌治疗后疾病复发患者的转录组差异。

    摘要Advanced breast cancer is characterised by enhanced tumour adaptability to therapeutic pressure and the metastatic microenvironment. Transcriptome differences in 14 primary breast tumour samples (n = 14 samples) are uncovered through this comparative RNA-seq analysis of patients that responded well to therapy (n = 7) and patients who had disease recurrence on endocrine treatment (n = 7). RNA sequencing data is deposited as log2 transformed median-of-ratios (DESeq2) normalised counts gene expression values (44934 genes IDs; n = 14 tumour samples).

人源·鼠源单细胞

Human · Mouse · Single-cell

  1. 01 GSE299631 对源自 KB1P 小鼠乳腺肿瘤模型的肿瘤组织进行治疗后采集,包括未治疗组、单次 TAC 治疗组和单次顺铂治疗组,分别在治疗后 7 或 12 天、肿瘤复发时采集残余和复发肿瘤组织,同时采集健康乳腺组织,采用空间转录组技术分析肿瘤组织的转录特征,比较不同治疗条件下肿瘤组织与健康组织的差异。 人源·鼠源 · 50 例 · GPL24247;24676 · 2025/06/19

    设计对源自 KB1P 小鼠乳腺肿瘤模型的肿瘤组织进行治疗后采集,包括未治疗组、单次 TAC 治疗组和单次顺铂治疗组,分别在治疗后 7 或 12 天、肿瘤复发时采集残余和复发肿瘤组织,同时采集健康乳腺组织,采用空间转录组技术分析肿瘤组织的转录特征,比较不同治疗条件下肿瘤组织与健康组织的差异。

    摘要Breast cancer remains one of the prominent causes of death worldwide. Although chemotherapeutic agents often result in substantial reduction of primary or metastatic tumors, remaining drug-tolerant tumor cell populations, known as minimal residual disease (MRD), pose a significant risk of recurrence and therapy resistance. In this study, we describe the spatiotemporal organisation of therapy response and MRD in BRCA1;p53-deficient mouse mammary tumors and human clinical samples using a multimodal approach. By integrating single-cell RNA sequencing, spatial transcriptomics, and imaging mass cytometry across multiple treatment timepoints, we characterise dynamic interactions between tumor cell subpopulations and their surrounding microenvironment. Our analysis identifies a distinct, drug-tolerant epithelial-mesenchymal transition (EMT) cancer cell population, which exhibits a conserved expression program in human BRCA1-deficient tumors and significantly correlates with adverse clinical outcomes. We further reveal the spatial distribution of residual EMT-like tumor cells within specific anatomical niches, providing a framework for understanding the persistence of MRD and potential therapeutic vulnerabilities. These findings yield a comprehensive molecular roadmap of MRD, opening new avenues for therapeutic strategies targeting EMT-driven drug tolerance and tumor relapse.

人源·鼠源bulk 转录组

Human · Mouse · Bulk RNA-seq

  1. 01 GSE3165 对108个独特的鼠类乳腺肿瘤模型和10个正常乳腺组织样本进行DNA微阵列分析,并与122个来自人类乳腺肿瘤和正常组织的微阵列数据进行比较,以识别人类和鼠类乳腺肿瘤之间的保守基因表达特征。研究对象为鼠类乳腺肿瘤模型和人类乳腺肿瘤组织,检测方式为DNA微阵列表达分析,主要比较不同鼠类模型与人类乳腺肿瘤亚型的表达模式。 人源·鼠源 · 354 例 · GPL887;1390;885;891 · 2007/05/01

    设计对108个独特的鼠类乳腺肿瘤模型和10个正常乳腺组织样本进行DNA微阵列分析,并与122个来自人类乳腺肿瘤和正常组织的微阵列数据进行比较,以识别人类和鼠类乳腺肿瘤之间的保守基因表达特征。研究对象为鼠类乳腺肿瘤模型和人类乳腺肿瘤组织,检测方式为DNA微阵列表达分析,主要比较不同鼠类模型与人类乳腺肿瘤亚型的表达模式。

    摘要Mice have been used as models for human breast cancers for many years, however, it is still unclear which murine models faithfully represent human tumor phenotypes. To address this question, we used DNA microarrays to characterize 10 different murine mammary models and compared these data to the expression patterns from primary human breast tumors. Hierarchical clustering analysis of the murine samples showed that the WAP-Myc, MMTV-Neu, MMTV-PyMT, WAP-Int3, and C3(1)-Tag tumors were highly correlated within each model. Other models, including the WAP-T_121 , MMTV-Wnt1, and DMBA-induced tumor model, did not show this consistency and gave rise to tumors with potentially different cell types of origin. A combined clustering analysis of the murine tumors with 102 human breast tumors showed many shared expression features. These features included a proliferation signature, an Interferon-regulated pattern, and patterns reflective of the presence of lymphocytes and fibroblasts. Murine tumors could be categorized according to their presumed cellular origins; the C3(1)-Tag, BRCA1+/-; p53+/-;IR, and DMBA-treated models displayed expression characteristics of human basal-like breast tumors; the MMTV-Neu, MMTV-PyMT, and WAP-Myc models shared features with human luminal breast tumors including the high expression of GATA3 and XBP1. In some cases, single mouse models did not reproduce the entire expression pattern seen in a specific human subtype; rather portions of a subtype’s expression profile were captured/represented by different murine models. The presence of shared patterns of expression between mice and humans provides a common framework for the direct comparison and integration of animal models with human breast Keywords: reference x sample

鼠源bulk 转录组

Mouse · Bulk RNA-seq

  1. 01 GSE32152 将野生型小鼠乳腺腺体与IGF-IR过表达诱导的原发性乳腺肿瘤(PMT)及IGF-IR下调后复发的纺锤体肿瘤(RST)样本进行比较,所有样本均与通用小鼠参考RNA杂交,通过微阵列分析检测基因表达差异。 鼠源 · 28 例 · GPL7202 · 2011/10/01

    设计将野生型小鼠乳腺腺体与IGF-IR过表达诱导的原发性乳腺肿瘤(PMT)及IGF-IR下调后复发的纺锤体肿瘤(RST)样本进行比较,所有样本均与通用小鼠参考RNA杂交,通过微阵列分析检测基因表达差异。

    摘要Molecular profiling was used to classify mammary tumors that develop in MTB-IGFIR transgenic mice. It was determined that the primary mammary tumors (PMT), which develop due to elevated expression of the type I insulin-like growth factor receptor (IGF-IR) in mammary epithelial cells, most closely resemble murine tumors with basal-like or mixed gene expression profiles and with human basal-like breast cancers. Downregulation of IGF-IR transgene in MTB-IGFIR tumor-bearing mice leads to the regression of most of the tumors followed by tumor re-appearance in some of the mice. These tumors that re-appear following IGF-IR transgene downregulation do not express the IGF-IR transgene and cluster with murine mammary tumors that express a mesenchymal gene expression profile and with human claudin-low breast cancers. Therefore, IGF-IR overexpression in murine mammary epithelial cells induces mammary tumors with primarily basal-like characteristics while tumors that develop following IGF-IR downregulation express a gene signature that most closely resembles human claudin-low breast tumors.

微信二维码

课题合作 · 扫码加微信

bioinformaticsboy